Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects

• Iqra Rahat,
• Pooja Yadav,
• Aditi Singhal,
• Mohammad Fareed,
• Jaganathan Raja Purushothaman,
• Mohammed Aslam,
• Raju Balaji,
• Sonali Patil-Shinde and
• Md. Rizwanullah

Beilstein J. Nanotechnol. 2024, 15, 1473–1497, doi:10.3762/bjnano.15.118

• specific enzymes can trigger drug release [74]. For instance, Wang et al. fabricated transferrin ligand-decorated redox-sensitive PLHNPs to achieve improved therapeutic efficacy of afatinib against non-small cell lung cancer [70][75]. The complete scheme for the development of ligand-decorated redox

Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

• Filip Gorachinov,
• Fatima Mraiche,
• Diala Alhaj Moustafa,
• Ola Hishari,
• Yomna Ismail,
• Jensa Joseph,
• Maja Simonoska Crcarevska,
• Marija Glavas Dodov,
• Nikola Geskovski and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2023, 14, 240–261, doi:10.3762/bjnano.14.23

• intracellular internalization, and bring advantages over conventional nanocarriers. Keywords: co-delivery nanoparticles; combinatorial therapy; EGFR TKI resistance; non-small cell lung cancer (NSCLC); overcoming and preventing resistance; Introduction Among the malignant diseases, lung cancer takes the lead

• recorded worldwide for both genders, representing 18% of all cancer deaths [4]. There are two main classes of lung cancer based on histological appearance, namely small-cell lung cancer (SCLC), which is highly aggressive, and non-small cell lung cancer (NSCLC), which is more prevalent (85% of all diagnosed

• impact on the discovery of novel therapies based on specific histological types and molecular signatures of cancer. Molecularly targeted therapies that have been developed for a subgroup of non-small cell lung cancer (NSCLC) with endothelial growth factor receptor (EGFR) activating mutations firmly

Orally administered docetaxel-loaded chitosan-decorated cationic PLGA nanoparticles for intestinal tumors: formulation, comprehensive in vitro characterization, and release kinetics

• Sedat Ünal,
• Osman Doğan and
• Yeşim Aktaş

Beilstein J. Nanotechnol. 2022, 13, 1393–1407, doi:10.3762/bjnano.13.115

• the proliferation of cancer cells [32][33][34]. Its potent activity against a wide spectrum of cancers such as colon cancer, gastric cancer, breast cancer, recurrent ovarian cancer, and non-small cell lung cancer has been elucidated by in vitro and in vivo studies [35]. Its poor water solubility

Systematic studies into uniform synthetic protein nanoparticles

• Nahal Habibi,
• Ava Mauser,
• Jeffery E. Raymond and
• Joerg Lahann

Beilstein J. Nanotechnol. 2022, 13, 274–283, doi:10.3762/bjnano.13.22

• -loaded HSA particles with diameters of approximately 130 nm [10][11]. Since then, AbraxaneTM has been used for non-small cell lung cancer, late-stage pancreatic cancer, and as a treatment for metastatic breast cancer [12][13]. Nevertheless, nab-based nanoparticles suffer from significant drawbacks, such

Use of nanosystems to improve the anticancer effects of curcumin

• Andrea M. Araya-Sibaja,
• Norma J. Salazar-López,
• Krissia Wilhelm Romero,
• José R. Vega-Baudrit,
• J. Abraham Domínguez-Avila,
• Carlos A. Velázquez Contreras,
• Ramón E. Robles-Zepeda,
• Mirtha Navarro-Hoyos and
• Gustavo A. González-Aguilar

Beilstein J. Nanotechnol. 2021, 12, 1047–1062, doi:10.3762/bjnano.12.78

• -cell lung cancer through the regulation of metastasis-associated protein 1 (MTA1), which is linked to tumor aggressiveness and metastasis, while its modulating effect is related to the suppression of the Wnt/β-catenin pathway. Curcumin also blocks pancreatic cancer metastases through PI3K/Akt/NF-ĸB

• highly dependent on angiogenesis [25], making this process a likely target to prevent, mitigate, or treat some types of cancer. Previous studies have reported the antiangiogenic activity of CUR against cancerous cells [26][27]. In fact, CUR has been shown to hinder proliferation and invasion of non-small

Electrokinetic characterization of synthetic protein nanoparticles

• Daniel F. Quevedo,
• Cody J. Lentz,
• Adriana Coll de Peña,
• Yazmin Hernandez,
• Nahal Habibi,
• Rikako Miki,
• Joerg Lahann and
• Blanca H. Lapizco-Encinas

Beilstein J. Nanotechnol. 2020, 11, 1556–1567, doi:10.3762/bjnano.11.138

• , non-small cell lung cancer, and pancreatic adenocarcinomas [9]. Current technologies allow for the synthesis of smart PNPs that release their active enzymatic load into oxidative environments [6]. A next step to further advance smart protein nanoparticle technologies is to develop a scalable method

Using gold nanoparticles to detect single-nucleotide polymorphisms: toward liquid biopsy

• María Sanromán Iglesias and
• Marek Grzelczak

Beilstein J. Nanotechnol. 2020, 11, 263–284, doi:10.3762/bjnano.11.20

• reported the detection of mutations in exon 19 and exon 21 of the epidermal growth factor receptor (EGFR) isolated from both the lung cancer cell lines and the cancer tissues of patients with non-small-cell lung cancer [66]. The citrate-stabilized gold nanoparticles underwent selective aggregation upon the

• addition of mutated DNA that hybridized with the complementary probe of 20 bases. Yet, the gold nanoparticles remained stable in the presence of wild-type DNA complementary to the probe sequence. In the eight specimens of non-small-cell lung cancer patients, the deletion of the mutant form of exon 19 and

Rational design of block copolymer self-assemblies in photodynamic therapy

• Maxime Demazeau,
• Laure Gibot,
• Anne-Françoise Mingotaud,
• Patricia Vicendo,
• Clément Roux and
• Barbara Lonetti

Beilstein J. Nanotechnol. 2020, 11, 180–212, doi:10.3762/bjnano.11.15

• the delivery of PDT sensitizers [120]. Many groups have explored this strategy since. More recently, one of the most often targeted cell-surface entities has been EGFR (epidermal growth factor receptor, overexpressed in a variety of solid tumors such as non-small cell lung cancer, head and neck

Bombesin receptor-targeted liposomes for enhanced delivery to lung cancer cells

• Mohammad J. Akbar,
• Pâmela C. Lukasewicz Ferreira,
• Melania Giorgetti,
• Leanne Stokes and
• Christopher J. Morris

Beilstein J. Nanotechnol. 2019, 10, 2553–2562, doi:10.3762/bjnano.10.246

• ]. In the lung cancer field, cisplatin formulated as a pegylated liposomal formulation (Lipoplatin®) has delivered comparable antitumour response against non-small cell lung cancer tumours with reduced side effects when delivered in combination with paclitaxel compared to when cisplatin and paclitaxel

Synthesis and potent cytotoxic activity of a novel diosgenin derivative and its phytosomes against lung cancer cells

• Liang Xu,
• Dekang Xu,
• Ziying Li,
• Yu Gao and
• Haijun Chen

Beilstein J. Nanotechnol. 2019, 10, 1933–1942, doi:10.3762/bjnano.10.189

• and synthesized, aiming to discover new steroid-based antitumor agents. In this work, we synthesized several Di derivatives and screened FZU-0021-194-P2 (P2), which showed more potent cytotoxic activities against human non-small-cell lung cancer A549 and PC9 cells. Considering that Di has a unique

• efficiently than Di phytosomes after 72 h of incubation time by inducing cell cycle arrest and apoptosis. The results indicated that P2Ps could be a promising anticancer formulation for non-small-cell lung cancer. Keywords: diosgenin; non-small-cell lung cancer; phytosomes; sterol structure; Introduction

• phytosomes were prepared by substituting Di and its derivative for cholesterol. The anticancer effects of free drugs and their phytosomes were investigated in non-small-cell lung cancer cells. Results and Discussion Synthesis and characterization of Di derivatives Late-stage functionalization that uses the C

Anticancer efficacy of a supramolecular complex of a 2-diethylaminoethyl–dextran–MMA graft copolymer and paclitaxel used as an artificial enzyme

• Yasuhiko Onishi,
• Yuki Eshita,
• Rui-Cheng Ji,
• Masayasu Onishi,
• Takashi Kobayashi,
• Masaaki Mizuno,
• Jun Yoshida and
• Naoji Kubota

Beilstein J. Nanotechnol. 2014, 5, 2293–2307, doi:10.3762/bjnano.5.238

• ] analyzed expression profiles of 807 genes of non-small cell lung cancer PC-14 cells after treatment with cisplatin (CDDP) incorporated in polymeric micelles (CDDP/m) versus free cisplatin. A total of 50 genes of significant differential expression between cells treated with free CDDP and CDDP/m were